


Solventum™ ActiV.A.C.™ Therapy System Applied with or without 3M™ Promogran Prisma™ Collagen Matrix with ORC and Silver

Hou Y and Griffin L. Comparative Effectiveness of Negative Pressure Wound Therapy with and without Oxidized Regenerated Cellulose/Collagen/Silver-ORC Dressing. *Adv Wound Care.* 2025; 14 (6): 285-294

Negative pressure wound therapy (NPWT) and Promogran Prisma Matrix are established wound-care modalities designed to support granulation and healing. Updated manufacturer guidance now includes use of the Promogran Prisma Matrix with the ActiV.A.C. Therapy System.

This study is the first comparative effectiveness analysis evaluating ActiV.A.C. Therapy System alone vs. ActiV.A.C. Therapy System combined with Promogran Prisma Matrix in outpatient care.

After propensity score matching, **wounds treated with ActiV.A.C. Therapy System and Promogran Prisma Matrix compared to ActiV.A.C. Therapy System alone:**



Were **9.5% more likely to improve or heal** with the combination vs. ActiV.A.C. Therapy alone

83.7% vs. 74.2% ($p = 0.00029$)

Achieved significantly **greater wound area reduction**

40% vs. 9% ($p = 0.0099$)

Conclusion:

This retrospective analysis introduces new evidence supporting the integrated use of Promogran Prisma Matrix with the ActiV.A.C. Therapy System. When used together, the therapies may enhance wound improvement, reduce wound worsening and accelerate optimal wound granulation, offering clinicians a potentially more effective outpatient approach.

Methods:

A retrospective review of the United States Wound Registry identified outpatient wounds treated with the ActiV.A.C. Therapy System either alone or with Promogran Prisma Matrix.

Patient Populations:

- **Pre-matching:** ActiV.A.C. Therapy System Alone (n = 485);
ActiV.A.C. Therapy System + Promogran Prisma Matrix (n = 485)
- **Post-matching:** ActiV.A.C. Therapy System Alone (n = 485);
ActiV.A.C. Therapy System + Promogran Prisma Matrix (n = 485)




Post-matching differences in patient demographics, comorbidities and wound characteristics were not statistically significant between groups

- **Mean age:** ActiV.A.C. Therapy System Alone (56.1 years);
ActiV.A.C. Therapy System + Promogran Prisma Matrix (57.1 years)
- **Initial wound size:** ActiV.A.C. Therapy System Alone (25.3 cm²);
ActiV.A.C. Therapy System + Promogran Prisma Matrix (22.3 cm²)

Results:

Percentage of wounds with optimal granulation tissue at the indicated time point




Granulation outcomes

Wounds treated with ActiV.A.C. Therapy System and Promogran Prisma Matrix compared to ActiV.A.C. Therapy System alone:

- Demonstrated higher rates of optimal granulation (**75–100% coverage**) at all examined time points
- Reached optimal granulation faster during the **first 90 days** ($p = 0.00034$)

Across both groups:



Solventum Medical Surgical
2510 Conway Avenue East
St. Paul, MN 55144-1000

Phone 800-228-3957
Web Solventum.com

Note:
Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. The length of the combined therapy for Promogran Prisma Matrix with ActiV.A.C. Therapy System should not exceed 30 days. Please consult product instructions for use prior to application. Rx only.

To learn more about how 3M™ Promogran™ Matrix Family can help benefit your patients, call 1-800-228-3957 or visit Solventum.com



Review full study details

Solventum, formerly 3M Health Care

© Solventum 2026. All Rights Reserved. Solventum and the S logo are trademarks of Solventum or its affiliates. 3M is a trademark of 3M. Other trademarks are the property of their respective owners.
US_70-2013-1864-2